CN117677403A - Gadolinium-based compounds and MRI contrast agents comprising the same - Google Patents
Gadolinium-based compounds and MRI contrast agents comprising the same Download PDFInfo
- Publication number
- CN117677403A CN117677403A CN202280051246.4A CN202280051246A CN117677403A CN 117677403 A CN117677403 A CN 117677403A CN 202280051246 A CN202280051246 A CN 202280051246A CN 117677403 A CN117677403 A CN 117677403A
- Authority
- CN
- China
- Prior art keywords
- compound
- disease
- mri contrast
- contrast agent
- do3a
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 53
- 239000002616 MRI contrast agent Substances 0.000 title claims abstract description 22
- 229910052688 Gadolinium Inorganic materials 0.000 title claims abstract description 13
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 title claims abstract description 12
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 25
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 25
- 229920000642 polymer Polymers 0.000 claims description 22
- 208000014644 Brain disease Diseases 0.000 claims description 15
- 208000024827 Alzheimer disease Diseases 0.000 claims description 11
- 230000002757 inflammatory effect Effects 0.000 claims description 11
- 230000003412 degenerative effect Effects 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 230000000626 neurodegenerative effect Effects 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 230000008499 blood brain barrier function Effects 0.000 claims description 5
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 5
- 238000010253 intravenous injection Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 abstract description 8
- HHLZCENAOIROSL-UHFFFAOYSA-N 2-[4,7-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid Chemical compound OC(=O)CN1CCNCCN(CC(O)=O)CCN(CC(O)=O)CC1 HHLZCENAOIROSL-UHFFFAOYSA-N 0.000 abstract description 2
- 150000002251 gadolinium compounds Chemical class 0.000 abstract 1
- 239000002872 contrast media Substances 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 238000002595 magnetic resonance imaging Methods 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- -1 2-ethoxy-2-oxoethyl Chemical group 0.000 description 5
- 230000003959 neuroinflammation Effects 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 125000005647 linker group Chemical group 0.000 description 4
- 230000005291 magnetic effect Effects 0.000 description 4
- 239000012046 mixed solvent Substances 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 3
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 3
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 description 3
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical group [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000003119 immunoblot Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000002314 neuroinflammatory effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 238000004896 high resolution mass spectrometry Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- RZESKRXOCXWCFX-UHFFFAOYSA-N 2-[bis[2-[carboxymethyl-[2-(methylamino)-2-oxoethyl]amino]ethyl]amino]acetic acid Chemical compound CNC(=O)CN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC(=O)NC RZESKRXOCXWCFX-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000031124 Dementia Alzheimer type Diseases 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 108010034143 Inflammasomes Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- ZPDFIIGFYAHNSK-UHFFFAOYSA-K gadobutrol Chemical compound [Gd+3].OCC(O)C(CO)N1CCN(CC([O-])=O)CCN(CC([O-])=O)CCN(CC([O-])=O)CC1 ZPDFIIGFYAHNSK-UHFFFAOYSA-K 0.000 description 1
- RJOJUSXNYCILHH-UHFFFAOYSA-N gadolinium(3+) Chemical compound [Gd+3] RJOJUSXNYCILHH-UHFFFAOYSA-N 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses a gadolinium-based compound and an MRI contrast agent containing the same. The gadolinium-based compound may be a DO 3A-based gadolinium compound to which protocatechuic acid is bound. The MRI contrast agent may comprise the compound. In addition, the present invention discloses a pharmaceutical composition for preventing or treating neuroinflammatory disorders comprising the compound or a pharmaceutically acceptable salt thereof.
Description
Technical Field
The present invention relates to gadolinium-based compounds and MRI contrast agents comprising the compounds.
Background
Today, as the population ages, patients suffering from degenerative brain diseases continue to grow, and the need for early detection of these diseases is becoming increasingly prominent. Neurotoxicity caused by excessive accumulation of beta-amyloid polymers (amyloid aβ) is considered to be one of the etiologies of degenerative brain diseases including parkinson's disease, vascular dementia, alzheimer's disease, and the like.
Beta-amyloid (aβ) is the major component of amyloid plaques found in the brains of alzheimer's patients, meaning a 36 to 43 amino acid peptide closely related to alzheimer's disease. The peptides are induced from Amyloid Precursor Protein (APP).
The beta-amyloid molecules can aggregate to form soluble polymers that can exist in a variety of forms, and the beta-amyloid polymers (oligometric aβ) formed are toxic to nerve cells and are well known to be directly involved in the progression of alzheimer's disease if excessively accumulated in the brain. Thus, it is expected that detecting changes in amyloid polymer concentration will enable early diagnosis of degenerative brain diseases.
Meanwhile, magnetic resonance imaging (Magnetic Resonance Image, hereinafter MRI) is a method for obtaining human anatomy, physiology, and biochemistry information images by utilizing the phenomenon that hydrogen atoms are relaxed in a magnetic field due to the difference in distribution of hydrogen atoms among tissues in a body. Unlike CT or PET, MRI does not use radiation harmful to the human body, but generates an image in vivo using magnetic field gradients and radio waves under a strong magnetic field, and thus is non-invasive, not only high in resolution, but also excellent for soft tissue examination.
In order to more precisely utilize such an MRI apparatus, a contrast agent (contrast agent) is injected into a subject to obtain an MRI image. Contrast (contrast) between tissues on an MRI image is a phenomenon that occurs due to relaxation (relaxation) of nuclear spins of water molecules within the tissues back to an equilibrium state, which acts differently on each tissue. The contrast agent influences the relaxation effect by using paramagnetic or superparamagnetic materials, and pulls the relaxation difference between tissues to cause MRI signal change, so that the contrast between the tissues is clearer.
At present, the most commonly used in clinicIs a gadolinium (Gd) chelate-based contrast agent. Currently, gd-DTPA is usedGd-DOTA/>Gd(DTPA-BMA)/>Gd(DO3A-HP)Gd(BOPTA)/>Etc. However, most commonly used contrast agents are non-specific contrast agents distributed in the extracellular space (extracellular fluide, ECF). As specific contrast agents only special liver specific contrast agents are used.
Recent studies have driven the development of contrast agents with specific targeting or which can exhibit signal enhancement by physiological activity (pH change, enzymatic activity), but to date, MRI contrast agents with specific targeting, in particular MRI contrast agents for degenerative brain parts, have not achieved adequate results.
Disclosure of Invention
It is an object of the present invention to provide a compound that specifically binds to a β -amyloid polymer.
It is another object of the present invention to provide an MRI contrast agent containing the above compound.
It is still another object of the present invention to provide a pharmaceutical composition for preventing or treating neuroinflammatory disorders, which contains the above-mentioned compound.
According to one aspect, the present invention provides a compound having the following formula (1):
in the method, in the process of the invention,
l is- (CH) 2 ) x -A 1 -(CH 2 ) y -A 2 -(CH 2 ) z -*，
x, y and z are each independently selected from any integer from 0 to 5,
A 1 a is a 2 Is independently selected from the group consisting of single bond, -COO-, -CO-, -NH-, -CH 2 One or more structures in the group of-CONH-and-O-,
x is a structure having the following formula (2):
* Is a binding site.
In one embodiment, the A 2 Can be-NH-.
In one embodiment, the A 1 Can be, -CONH-.
In one embodiment, x may be 1.
In one embodiment, y may be 2.
In one embodiment, z may be 0.
In one embodiment, the compound may have the following formula (3).
In one embodiment, the gadolinium (Gd) may coordinate with more than one water molecule.
In one embodiment, the compound may specifically bind to mammalian β -amyloid polymers (oligomera).
In one embodiment, the compound may have a relaxation rate (relaxation) of 3.5 to 4.4s -1 。
In one embodiment, the compound may cross the Blood Brain Barrier (BBB) when injected by intravenous injection.
According to another aspect, the present invention provides an MRI contrast agent comprising a compound as described above.
In one embodiment, the MRI contrast agent may be used to diagnose degenerative brain diseases.
In one embodiment, the MRI contrast agent is used to diagnose Alzheimer's (Alzheimer's) disease.
According to still another aspect, the present invention provides a pharmaceutical composition for preventing or treating neuroinflammatory disorders, comprising the above-described compound or a pharmaceutically acceptable salt thereof.
In one embodiment, the neuroinflammatory disorder may be an inflammatory neurodegenerative brain disorder.
In one embodiment, the inflammatory neurodegenerative brain disease may be a disease selected from Alzheimer's disease or parkinson's disease.
Effects of the invention
According to the embodiment of the invention, the compound can be specifically combined with the beta-amyloid polymer, so that the MRI contrast agent containing the compound can be used for diagnosing degenerative brain diseases including Alzheimer's disease.
In addition, the compound according to the embodiment of the present invention can be used as an active ingredient in a pharmaceutical composition for preventing or treating neuroinflammatory diseases by having antioxidant and anti-inflammatory functions to reduce oxidative stress causing neuroinflammation, and reducing inflammatory factors expressed in a pathway causing neuroinflammation, i.e., NLRP3, ASC, etc.
Drawings
Fig. 1 to 9 are diagrams showing experimental results of experimental examples according to the present invention.
Detailed Description
Hereinafter, embodiments of the present invention will be described in detail with reference to the accompanying drawings. The invention is susceptible to various modifications and alternative forms, and specific embodiments thereof have been shown by way of example in the drawings and are herein described in detail. It should be understood, however, that there is no intention to limit the invention to the specific forms disclosed, but on the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention. In describing the drawings, like reference numerals are given to like components. In the drawings, the size of the structures is shown exaggerated in comparison with actual ones for the sake of clarity of the invention.
The terminology used in the present application is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. The singular reference includes the plural reference unless the context clearly indicates otherwise. In this application, the terms "comprises" and "comprising" are used to specify the presence of stated features, integers, steps, actions, components or groups thereof, but do not preclude the presence or addition of one or more other features or integers, steps, actions, components or groups thereof.
Unless defined otherwise, all terms used in this application, including technical and scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Terms defined in commonly used dictionaries should be interpreted as having meanings consistent with their meanings in the context of the relevant art and should not be interpreted in an idealized or overly formal sense unless expressly so defined herein.
The compound according to an embodiment of the present invention may have the following formula (1).
In the above formula (1), gadolinium ion (Gd) 3+ ) Can be combined with a carboxylate (carboxylate; COO-) groups coordinate to form complexes.
In the above formula (1), L may be- (CH) 2 ) x -A 1 -(CH 2 ) y -A 2 -(CH 2 ) z And x, y and z may each be independently selected from any integer from 0 to 5. A is that 1 A is a 2 Can be each independently selected from the group consisting of single bond, -COO, -CO, -NH, -CH 2 -*、*-More than one structure in the CONH-, and-O-/group. * Is a binding site.
The L may be a linker (linker) linking the nitrogen in the cyclic structure of the compound and the X. The A is 1 A is a 2 The method of connecting nitrogen in the cyclic structure of the compound and the X through the linking group or the functional group determined by the method may be determined. The x, y and z may determine the linking of the A in the linker 1 And A 2 Is a chain length of the chain. In one embodiment, the A 2 Can be-NH-. In one embodiment, the A 1 Can be, -CONH-. In one embodiment, x may be 1. In one embodiment, y may be 2. In one embodiment, z may be 0.
As long as the compound according to an embodiment of the present invention actually has the structure of the above formula (1), bonding or removal of bonding acceptable to those of ordinary skill in the art is not excluded in the scope of the present invention. As an example, in one embodiment, the gadolinium (Gd) may be coordinated with more than one water molecule in the compound.
In the above formula (1), X may have a structure of the following formula (2).
* Is a binding site.
In one embodiment, the compound may have the following formula (3).
In one embodiment, the compound may specifically bind to mammalian β -amyloid polymers (oligomera). In one embodiment, the compound may have 3.5 to 4.4s -1 Relaxation rate (relaxation) of (c). In one embodiment, the compound may cross the Blood Brain Barrier (BBB) when injected by intravenous injection.
As described above, the compounds according to embodiments of the present invention may specifically bind to β -amyloid polymer.
An MRI contrast agent according to an embodiment of the present invention may comprise the compound. In one embodiment, the MRI contrast agent may be used to diagnose degenerative brain diseases. In one embodiment, the MRI contrast agent may be used to diagnose Alzheimer's disease.
As described above, the MRI contrast agent according to the embodiment of the present invention may be used to diagnose degenerative brain diseases including alzheimer's disease.
A pharmaceutical composition for preventing or treating neuroinflammatory disorders according to an embodiment of the present invention may comprise the above-described compound or a pharmaceutically acceptable salt thereof. In one embodiment, the neuroinflammatory disorder may be an inflammatory neurodegenerative brain disorder. In one embodiment, the inflammatory neurodegenerative brain disease may be a disease selected from Alzheimer's disease or parkinson's disease.
In one embodiment, the "pharmaceutically acceptable salt" is not limited as long as it forms an addition salt with the compound, and includes salts derived from pharmaceutically acceptable inorganic acids, organic acids, or bases. The compound according to the present invention may be converted into a salt thereof by a conventional method, and a person of ordinary skill in the art can easily prepare a salt according to the structure of the compound without additional explanation.
The pharmaceutical composition of the present invention may contain the compound represented by formula 1 above or a pharmaceutically acceptable salt thereof alone, but may further contain a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier may be one commonly used in the pharmaceutical field, and may be an excipient (e.g., starch, calcium carbonate, sucrose, lactose, sorbitol, mannitol, cellulose, etc.) or a diluent (e.g., physiological saline solution, purified water, etc.).
In the present invention, the term "preventing" is to inhibit the occurrence of a neuroinflammatory condition or disease in an individual who is not diagnosed as having such condition or disease, but who is susceptible to such condition or disease. In addition, in the present invention, the term "treating" refers to inhibiting the development of, alleviating, and eliminating a neuroinflammatory condition or disease.
The pharmaceutical compositions of the present invention may be prepared in various dosage forms for parenteral or oral administration according to well-known methods.
Hereinafter, embodiments of the present invention will be described in detail. However, the examples described below are only partial examples of the present invention, and the scope of the present invention is not limited to the following examples.
< Synthesis of Gd-DO3A-Pca >
The Gd-DO3A-Pca compound is prepared by stepwise synthesis of material 1 to final material 5.
(1) Synthesis of tri-tert-butyl2,2 '- (10- (2-ethoxy-2-oxoethyl) -1,4,7,10-tetraazacyclododecane-1,4, 7-triyl) triacetate (tri-tert-butyl 2,2' - (10- (2-ethoxy-2-oxoethyl) -1,4,7, 10-tetrazacyclodecane-1, 4, 7-yl) triacetate), 1
Tri-tert-butyl2,2 '-1, 4,7,10-tetraazacyclododecane-1,4, 7-triyl) triacetate (tri-tert-butyl 2,2' - (1, 4,7, 10-tetraazacyclodecane-1, 4, 7-yl) triacetate) (9.72 mmol) was dissolved in 160mL of acetonitrile, followed by addition of potassium hydrogencarbonate (29.69 mmol) and stirring for 30 minutes. Then, ethyl bromoacetate (10.69 mmol) was added thereto, followed by stirring at 60℃for 24 hours. After 24 hours, the product was filtered with a filter and the solvent was removed by filtration under reduced pressure. The product was dissolved in dichloromethane, the insoluble material was removed, and after all solvents were removed, vacuum drying was performed to give a yellowish solid. Yield: 99 percent of
(2) Synthesis of tri-tert-butyl2,2 '- (10- (2-oxo-2- ((2- (3, 4, 5-trihydroxybenzoylamino) ethyl) amino) ethyl) -1,4,7,10-tetraazacyclododecane-1,4, 7-triyl) triacetate (tri-tert-butyl 2,2' - (10- (2-oxo-2- ((2- (3, 4, 5-trihydroxybenzamiddo) ethyl) amino) ethyl) -1,4,7, 10-tetrazacyclodecane-1, 4, 7-yl) triacylate), 2
After 1 (5.33 mmol) was dissolved in 7mL of methanol, 6mL of ethylenediamine was added and reacted at room temperature for 4 days. The solvent was removed after heating to 55 ℃ in vacuo to give an oily solid which was washed multiple times with diethyl ether. After drying in vacuo, insoluble matter dissolved in methanol was removed by filtration, and then a pale yellow solid was purified by column chromatography under a mixed solvent of methylene chloride/methanol. Yield: 57%
(3) Synthesis of tri-tert-butyl2,2 '- (10- (2- ((2- (3, 4-dihydroxybenzamido) ethyl) amino) -2-oxoethyl) -1,4,7,10-tetraazacyclododecane-1,4, 7-triyl) triacetate 2,2' - (10- (2- ((2- (3, 4-dihydroxybenzamido) ethyl) amino) -2-oxoethyl) -1,4,7, 10-tetraazacyclodecane-1, 4, 7-yl) triacetate, 3
Protocatechuic acid (6.97 mmol) was dissolved in dimethylformamide and stirred at a temperature of 0 ℃. Then, EDC. HCl (7.67 mmol) and HOBt hydrate (7.67 mmol) dissolved in dimethylformamide were added to the gallic acid solution and stirred for 30 minutes. Then, 2 (4.88 mmol) dissolved in dimethylformamide was added to the reaction mass, DIPEA (13.94 mmol) was added, and stirred at room temperature for 24 hours. Then, after concentrating dimethylformamide to the maximum by filtration under reduced pressure, extraction was performed with methylene chloride and brine (brine), dehydration was performed with sodium sulfate, and filtration under reduced pressure was performed. Then, the solid was separated by column chromatography under a mixed solvent of methylene chloride/methanol. The next reaction can be carried out without additional isolation and purification.
(4) Synthesis of 2,2 '- (10- (2- ((2- (3, 4-dihydroxybenzamido) ethyl) amino) -2-oxoethyl) -1,4,7,10-tetraazacyclododecane-1,4, 7-triyl) triacetate (2, 2' - (10- (2- ((2- (3, 4-dihydroxybenzamido) ethyl) amino) -2-oxoethyl) -1,4,7, 10-tetrazacyclodecane-1, 4, 7-yl) triacid), 4
After adding excess trifluoroacetic acid to 3 at a temperature of 0 ℃, the reaction was stirred at room temperature for 20 hours. Then, methylene chloride was added and filtration under reduced pressure was repeated. Next, high performance liquid chromatography was performed with the addition of 0.1% trifluoroacetic acid in water/acetonitrile mixed solvent to obtain a purified solid. Yield (2→4): 12%
(5) Synthesis of Gd-DO3A-Pca,5
4 (0.76 mmol) was dissolved in water, then the pH was adjusted to 3 using 1M sodium hydroxide, and GdCl dissolved in water was added 3 ·6H 2 O (0.53 mmol). Then, after the pH was adjusted to 7 using 1M sodium hydroxide, the mixture was stirred at room temperature for 20 hours. The solid obtained by the filtration under reduced pressure was separated and purified by high performance liquid chromatography with the addition of a water/acetonitrile mixed solvent of 10mM ammonium acetate to obtain a solid. Yield: 69%
HR-MS and purity analysis results of Gd-DO3A-Pca ]
Gd-DO3A-Pca was analyzed by HR-MS. Fig. 1 is a graph showing the result. Referring to FIG. 1, it was confirmed that a peak (738.1731 m/z) corresponding to the peak predicted for Gd-DO3A-Pca (738.1734 m/z) occurred.
Further, the results of analyzing the purity of Gd-DO3A-Pca using HPLC are shown in FIG. 2. Referring to FIG. 2, it was confirmed that the purity of Gd-DO3A-Pca was about 98%.
< Gd-DO3A-Pca Performance evaluation method and results >
1) Measurement of relaxation Rate (relaxation)
Using synthetic Gd-DO3A-Pca and cyclic conventional contrast agentsAnd->As a control group, the relaxation rate (r 1 、r 2 ). Specifically, after preparing a model by diluting gadolinium complex with triple distilled water to 5 concentrations (0.0625, 0.125, 0.25, 0.5, 1 mM), T was measured in 3T MRI 1 And T 2 Relaxation time (Relaxation time). From this, R (Relaxation rate=1/T) at each concentration was calculated, and the Relaxation rate (R) of gadolinium complex was obtained by linear regression analysis (see fig. 3) 1 、r 2 ) Results of (3)And is shown in table 1 below.
[ Table 1 ]
Referring to Table 1 above, it can be seen that r of Gd-DO3A-Pca 1 Has a value of 3.6.+ -. 0.1, r 2 Having a value of 4.3.+ -. 0.1 is a relaxation rate value sufficient for clinical use, and thus, it was confirmed that Gd-DO3A-Pca can be used as a contrast agent.
2) Evaluation of kinetic stability (Kinetic stability)
After preparing the model by diluting Gd-DO3A-Pca and various conventional contrast agents to a concentration of 2.5mM in PBS (pH 7.4), 1 equivalent of 250mM zinc chloride (ZnCl) was added 2 ) The binding stability of DO3A ligand and Gd metal ion was evaluated. This can be confirmed by measuring the metal exchange reaction (transition) of zinc ions to gadolinium ions as a change in relaxation rate.
From the observation of FIG. 4 showing the results, it was confirmed that Gd-DO3A-Pca of the present invention was due to R 2 The rate of change remains large, above 0.9, and therefore has sufficient stability to be used as an MRI contrast agent.
3) Evaluation of pH stability
1mM Gd-DO3A-Pca and conventional contrast agent as control groupDiluted in buffer solution of pH1, 3, 5, 7, 9, 11, then photographed on MRI 2 Weighted image 3 week measurement R 2 Values. By measuring R over time 2 The value, the change in value after dilution can be confirmed, and the more constant the value is, the higher the pH stability can be evaluated.
From FIG. 5 showing the results, gd-DO3A-Pca of the present invention showed R in the range of pH3-9 for 3 weeks 2 The values did not change much even under the strong acid-base conditions of pH1 and pH 11. From this result, it was confirmed that Gd-DO3A-Pca was stable under in vivo pH conditions and remained stable even under strong acid-base conditions.
4) Analysis of antioxidant Effect
The free radical scavenging ability of Gd-DO3A-Pca was evaluated by a 2, 2-Diphenyl-1-trinitrophenylhydrazine (2, 2-Diphenyl-1-picryl-hydrazyl, DPPH) test. As a control group, protocatechuic acid and vitamin C (ascorbic acid) which is a representative antioxidant substance were used. DPPH free radical is dark purple and turns yellow after being reduced by reaction with antioxidant substances. Since the redox reaction is changed in absorbance at a wavelength of 517nm, the antioxidant effect of Gd-DO3A-Pca can be confirmed by measuring the change. In the present invention, gd-DO3A-Pca (0, 5, 10, 20, 30 uM) at various concentrations was added to DPPH solution (final concentration 100 uM) dissolved in ethanol, absorbance was measured after reaction in the dark for 30 minutes, and the antioxidant effect was analyzed, and the results thereof are shown in FIG. 6.
Referring to fig. 6, gd-DO3A-Pca showed higher radical scavenging ability than protocatechuic acid and representative antioxidant substances of vitamin C (ascorbic acid) of the control group. These results indicate that Gd-DO3A-Pca has excellent effects of inhibiting oxidative stress.
5) Beta-amyloid polymer targeting evaluation
5-1) model Experimental methods for confirming targeting of beta-amyloid polymers
(1) 221.5uL of HFIP was added to 1mg of beta-amyloid protein at 1mM concentration, and then shaken at room temperature using a shake flask for 1 hour to remove pre-aggregation (Preaggregation).
(2) After drying the pre-aggregated β -amyloid removed, 221.5uL of DMSO was added to prepare a 1mM concentration, and a suspension was formed by a mixer and sonicator, followed by 878.5uL of PBS (1 x, ph 7.4) to prepare a 0.2mM concentration.
(3) After 4 days of incubation at 37℃using shake flasks, the polymerized beta-amyloid polymer was partitioned into 200uL each and Gd-DO3A-Pca and conventional contrast medium dissolved in PBS at a concentration of 2mMAfter 20uL addition, the cells were cultured at 37℃for 24 hours using a shake flask.
(4) After 24 hours, the supernatant was removed by centrifugation, and then after washing the β -amyloid polymer with PBS, 200uL of a solution of PBS: dmso=9:1 was added to the precipitate (Pellet) to prepare an MRI model sample. As a control, a model sample was used that only cultures the β -amyloid polymer.
5-2) analysis results of targeting effect of beta-amyloid Polymer
Using the model samples, gd-DO3A-Pca and conventional contrast agents according to embodiments of the invention were evaluated on a 9.4T MR deviceIs targeted by the beta-amyloid polymer.
Referring to FIG. 7 showing the results, only the model of the beta-amyloid polymer (Abeta) was cultured and incubated withThere was little contrast enhancement effect difference between the models (aβ+gadovist), but the model treated with Gd-DO3A-Pca (aβ+gd-DO 3A-Pca) showed a 2-fold increase in signal intensity compared to the model in which the β -amyloid polymer alone was cultured. From this, it was confirmed that the gadolinium contrast agent of the present invention has a targeting effect on β -amyloid polymer. .
Beta-amyloid polymers and fibrils formed by aggregation of overexpressed beta-amyloid accumulate in the brain, producing toxicity and destroying nerve cells, thus the so-called alzheimer's disease of degenerative brain diseases. The Gd-DO3A-Pca according to the embodiment of the invention has the function of targeting beta-amyloid polymer (toxic protein), and thus can have the function of diagnosing Alzheimer's disease.
6) In vitro (in vitro) toxicity evaluation
Experiments were performed to evaluate cytotoxicity on the mouse microglial cell line BV-2 cells, and the results are shown in fig. 8.
Referring to FIG. 8, when Gd-DO3A-Pca was treated at different concentrations (0, 100, 200, 400, 800. Mu.M), cell viability showed 78% at 800. Mu.M and up to a high concentration of 400. Mu.M, cell viability showed results exceeding 80%.
In an in vitro experiment using BV-2 cells, gd-DO3A-Pca was preferably treated to 400. Mu.M in view of a slight decrease in cell viability at high concentrations exceeding 800. Mu.M.
7) In vitro (in vitro) efficacy evaluation
BV-2 cells are activated by LPS (Lipopolysaccharides) and are therefore commonly used in neuroinflammatory cell experiments. Will be 5X 10 4 BV-2 cell seeding (seeding) 200ng LPS derived from E.coli (Escherichia coli) O127:B8 was treated in 6 wells and in serum-free medium (serum free media). After 4 hours LPS was removed and Gd-DO3A-Pca was treated at different concentrations (0, 100, 200, 400 uM) and after 20 hours Griess assay was performed using cell supernatants. The expression level of inflammatory factors was confirmed by immunoblotting (western blot) on the recovered cells. In this experiment, cells not treated with LPS were tested together with Gd-DO3A-Pca groups treated with normal BV-2 cells to confirm the individual effect of Gd-DO3A-Pca on BV-2 cells.
Oxidative stress, protein aggregation, and various inflammatory cytokines play a role in the process of causing neuroinflammation. As can be seen from fig. 9, gd-DO3A-Pca inhibits free radicals NO (nitric oxide) and iNOS (inducible nitric oxide synthase) induced by LPS, acting to reduce oxidative stress.
Further, it was confirmed that the NO-scavenging ability was increased according to the concentration of Gd-DO3A-Pca by quantifying NO expressed by Griess assay, and that the inhibition by Gd-DO3A-Pca was confirmed as in NO by quantitative analysis of the amount of NO synthase iNOS by immunoblotting (western blot).
In addition, it is known that neuroinflammation affects the development of neurodegenerative diseases such as dementia and parkinson's disease. Moreover, it was found that NLRP3 inflammatory small body pathway (inflammasome pathway) and the like causing neuroinflammation, and FIG. 9 of immunoblotting (western blot) results, it was confirmed that Gd-DO3A-Pca reduced inflammatory factors expressed in the pathway (pathway), so-called NLRP3, ASC and the like.
Although the invention has been described with reference to preferred embodiments thereof, it will be understood by those skilled in the art that various modifications and changes may be made thereto without departing from the spirit and scope of the invention as set forth in the appended claims.
Claims (15)
1. A compound, wherein, having the following formula (1):
in the method, in the process of the invention,
l is- (CH) 2 ) x -A 1 -(CH 2 ) y -A 2 -(CH 2 ) z -*，
x, y and z are each independently selected from any integer from 0 to 5,
A 1 a is a 2 Is independently selected from the group consisting of single bond, -COO-, -CO-, -NH-, -CH 2 One or more structures in the group of-CONH-and-O-,
x is a structure having the following formula (2):
* Is a binding site.
2. The compound of claim 1, wherein the a 2 is-NH-.
3. The compound of claim 2, wherein the a 1 is-CONH-.
4. A compound according to claim 3, wherein x is 1, y is 2 and z is 0.
5. The compound according to claim 1, wherein the compound has the following formula (3).
6. The compound of claim 1, wherein the gadolinium (Gd) coordinates with more than one water molecule.
7. The compound of claim 1, wherein the compound specifically binds to mammalian β -amyloid polymer (oligo aβ).
8. The compound of claim 1, wherein the compound has a relaxation rate of 3.5 to 4.4s -1 。
9. The compound of claim 1, wherein the compound crosses the blood brain barrier when injected by intravenous injection.
10. An MRI contrast agent comprising a compound according to any one of claims 1 to 9.
11. The MRI contrast agent of claim 10, wherein the MRI contrast agent is used to diagnose degenerative brain diseases.
12. The MRI contrast agent of claim 11, wherein the MRI contrast agent is used to diagnose alzheimer's disease.
13. A pharmaceutical composition for preventing or treating a neuroinflammatory disorder, comprising a compound according to any one of claims 1 to 9, or a pharmaceutically acceptable salt thereof.
14. The pharmaceutical composition of claim 13, wherein the neuroinflammatory disorder is an inflammatory neurodegenerative brain disorder.
15. The pharmaceutical composition of claim 14, wherein the inflammatory neurodegenerative brain disease is a disease selected from alzheimer's disease or parkinson's disease.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2021-0095647 | 2021-07-21 | ||
| KR10-2022-0089895 | 2022-07-20 | ||
| KR1020220089895A KR102659229B1 (en) | 2021-07-21 | 2022-07-20 | Gadolinium-based compound, mri contrast agent comprising the same |
| PCT/KR2022/010743 WO2023003411A1 (en) | 2021-07-21 | 2022-07-21 | Gadolinium-based compound and mri contrast agent comprising same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117677403A true CN117677403A (en) | 2024-03-08 |
Family
ID=90071692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280051246.4A Pending CN117677403A (en) | 2021-07-21 | 2022-07-21 | Gadolinium-based compounds and MRI contrast agents comprising the same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117677403A (en) |
-
2022
- 2022-07-21 CN CN202280051246.4A patent/CN117677403A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6542748B2 (en) | CEST system showing concentration-independent response | |
| EP3551614B1 (en) | Dimeric contrast agents | |
| KR102515879B1 (en) | Novel gadolinium-based compound, method for the preparation thereof, and mri contrast agent comprising the same | |
| EP3544964B1 (en) | High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging | |
| EP1163231B1 (en) | Perfluoroalkylamide, the production thereof and the use thereof in diagnostics | |
| JP5291930B2 (en) | Complex compound and MRI probe comprising the same | |
| CN117677403A (en) | Gadolinium-based compounds and MRI contrast agents comprising the same | |
| US20230233714A1 (en) | Novel gadolinium-based compound, method for producing same, and mri contrast agent containing same | |
| EP4374882A1 (en) | Gadolinium-based compound, and mri contrast agent including same | |
| EP4374881A1 (en) | Gadolinium-based compound and mri contrast agent comprising same | |
| KR102659248B1 (en) | Gadolinium-based compound, mri contrast agent comprising the same | |
| KR102659229B1 (en) | Gadolinium-based compound, mri contrast agent comprising the same | |
| US20230094602A1 (en) | Novel gadolinium-based compound, preparation method therefor, and mri contrast agent containing same | |
| EP4374883A1 (en) | Gadolinium-based compound, and mri contrast agent including same | |
| CN117677404A (en) | Gadolinium-based compounds and MRI contrast agents comprising the same | |
| CN117980008A (en) | Gadolinium-based compounds and MRI contrast agents comprising the same | |
| KR20230014663A (en) | Gadolinium-based compound, mri contrast agent comprising the same | |
| KR102515875B1 (en) | Novel gadolinium-based compound, method for the preparation thereof, and mri contrast agent comprising the same | |
| CN111886226A (en) | Compound having novel structure, anti-inflammatory agent and cyclooxygenase-2 inhibitor comprising the same | |
| KR102667904B1 (en) | Gadolinium-based compound, mri contrast agent comprising the same | |
| US5888476A (en) | Magnetic resonance blood pool agents | |
| KR102646267B1 (en) | Gadolinium-based compound, mri contrast agent comprising the same | |
| EP3386953B1 (en) | Contrast agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |